[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemoradiation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemoradiation":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,67,84,109,133],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":14,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100530044",false,"NCT06181656","Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation","Inclusion Criteria:\n\n1. Group 1A\n\n   a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.\n2. Group 1B\n\n   a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)\n3. Group 2A\n\n   a. Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer.\n4. Group 2B\n\n   a. Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer.\n5. Group 3\n\n   a. Healthy age- and gender- matched individuals\n6. All Groups\n\n   1. Patients of all genders, races and nationalities will be solicited.\n   2. Age \\>18 years\n   3. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy\n\n  a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Individuals with previous pneumococcal vaccination in the last 5 years.\n* Individuals with severe allergy to any of the vaccine components",true,"ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","OBSERVATIONAL","To learn how radiation treatment may affect your responses to vaccines against pneumonia.",[23,24,25,26],"Pneumococcal Vaccine","Esophageal Cancer","Lymphopenia","Chemoradiation","RECRUITING","2026-05-19",{"date":30,"type":31},"2026-05-20","ACTUAL",{"date":33,"type":31},"2024-02-05",{"date":35,"type":19},"2027-07-04",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100425581","NCT04821843","Neoadjuvant Treatment Modalities in Esophageal Cancer","Cohort Study of Neoadjuvant Treatment Modalities for Esophageal Cancer","Inclusion Criteria:\n\n* ≥18 years；\n* Esophageal or Esophagogastric cancer；\n* Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa (AJCC 8th)；\n* Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；\n* ECOG PS score: 0\\~1；\n* Estimated survival time ≥3 months；\n* Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g\u002FL ;Leukocytes: greater than or equal to 4,000 G\u002FL; Neutrophil: greater than or equal to 2,000 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml\u002Fmin; AST\u002FALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit；\n* Informed consent；\n\nExclusion Criteria:\n\n* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；\n* Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；\n* Existing active infection such as active tuberculosis and hepatitis；\n* History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；\n* Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin；\n* Participation in other clinical trials currently or within 4 weeks of selection；\n* Pregnant or lactating females；\n* Absence of medical records.",{"count":47,"type":19},2000,"INTERVENTIONAL",[50],"PHASE3","Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1\u002FPD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.",[24,53,26,54,55,56,57],"Chemotherapy Effect","Surgery","Targeted Therapy","Immunotherapy","Esophagogastric Juction Cancer","2026-01-18",{"date":60,"type":31},"2026-01-21",{"date":62,"type":31},"2002-01-01",{"date":64,"type":19},"2030-12-31",{"name":66,"class":38},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":68,"slug":4,"hasResults":10,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":48,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":82,"locationsCount":83},"100425577","NCT04821778","Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer","Cohort Study of Definitive Chemoradiotherapy for Esophageal or Esophagogastric Junction Cancer","Inclusion Criteria:\n\n* ≥18 years；\n* Esophageal or Esophagogastric cancer；\n* Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa(AJCC 8th)；\n* Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；\n* ECOG PS score: 0\\~1；\n* Estimated survival time ≥3 months；\n* Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g\u002FL ;Leukocytes: greater than or equal to 4,000 G\u002FL; Neutrophil: greater than or equal to 2,000 G\u002FL; Platelets: greater than or equal to 100,000\u002Fmm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml\u002Fmin; AST\u002FALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit；\n* Informed consent；\n\nExclusion Criteria:\n\n* With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；\n* Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；\n* Existing active infection such as active tuberculosis and hepatitis；\n* History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；\n* Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin；\n* Participation in other clinical trials currently or within 4 weeks of selection；\n* Pregnant or lactating females；\n* Absence of medical records.",{"count":47,"type":19},[50],"Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1\u002FPD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.",[77,78,26,55,56,53],"Esophagus Cancer","Esophagogastric Junction Cancer",{"date":60,"type":31},{"date":62,"type":31},{"date":64,"type":19},{"name":66,"class":38},5,{"id":85,"slug":4,"hasResults":10,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":39},"100346601","NCT03792854","Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)","LANACARE","Inclusion Criteria:\n\n* histologically proven anal cancer without distant metastases\n* indication for definitive chemoradiation therapy based on multidisciplinary evaluation\n* age \\>=18 years\n* written informed consent\n* ability to answer the standardized questionaires according to the treating physician\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* prior systemic therapy with regard to anal cancer\n* distant metastases\n* second malignancy",{"count":91,"type":19},100,"Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer",[94,95,26],"Anal Cancer","Quality of Life",[97,98,99],"anal cancer","quality of life","chemoradiation","2019-01-02",{"date":102,"type":31},"2019-01-03",{"date":104,"type":31},"2018-12-01",{"date":106,"type":19},"2026-12",{"name":108,"class":38},"Ludwig-Maximilians - University of Munich",{"id":110,"slug":4,"hasResults":10,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":39},"100341864","NCT03731130","Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer","Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer","NEOCARE","Inclusion Criteria:\n\n* histologically proven rectal Cancer without distant metastases\n* indication for neoadjuvant Radiation or chemoradiation therapy according to multidiciplinary Evaluation\n* age \\>=18 years\n* written informed consent\n* ability to answer the standardized questionaires according to the treating physician\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* prior systemic therapy with regard to rectal Cancer\n* distant metastasis\n* second malignancy",{"count":91,"type":19},"Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional Outcome, oncological outcome and toxicity in patients treated with neoadjuvant short term radiation or long-term chemoradiation followed by surgery",[119,95,120,26],"Rectal Cancer","Radiation Therapy",[122,98,123,124,99],"rectal cancer","neoadjuvant","radiation therapy","2018-11-02",{"date":127,"type":31},"2018-11-06",{"date":129,"type":31},"2018-10-05",{"date":131,"type":19},"2026-12-31",{"name":108,"class":38},{"id":134,"slug":4,"hasResults":10,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":39},"100340458","NCT03712774","Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer","ESOCARE","Inclusion Criteria:\n\n* histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant metastases (except supraclavicular nodes)\n* indication for neoadjuvant or definitive chemoradiation using either cisplatin\u002F5-FU or carboplatin\u002Fpaclitaxel with curative intent\n* age \\>= 18 years\n* written informed consent\n* ability to answer the standardized questionaires according to the treating physician\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* Treatment with palliative intent\n* distant metastases (except supraclavicular nodes)\n* second malignancy\n* Prior systemic treatment for esophageal Cancer\n* Treatment in an interventional study",{"count":140,"type":19},60,"Prospective observational study to evaluate the Quality of life based on standardized EORTC questionaires as well as toxicities, functional and oncological outcomes in patients treated with neoadjuvant or definitive chemoradiation for esophageal Cancer.",[95,26,24],[98,123,144,99,145],"definitive","esophageal cancer","2018-10-18",{"date":148,"type":31},"2018-10-19",{"date":150,"type":31},"2018-10-12",{"date":131,"type":19},{"name":108,"class":38},""]